Thrombotic Microangiopathy Syndromes—Common Ground and Distinct Frontiers
- 8 July 2022
- journal article
- review article
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 29 (2) , 149-160.e1
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R21-AG047036)
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases (K24-DK091419, R01-DK078106, R01-DK096920, U01-DK102163)
This publication has 103 references indexed in Scilit:
- Overview of Complement Activation and RegulationSeminars in Nephrology, 2013
- Partial ADAMTS13 deficiency in atypical hemolytic uremic syndromeBlood, 2013
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Emerging role of the mannose-binding lectin-dependent pathway of complement activation in clinical organ transplantationCurrent Opinion in Organ Transplantation, 2011
- Clinical Features of Malignant Hypertension with Thrombotic MicroangiopathyClinical and Experimental Hypertension, 2011
- Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulationPediatric Nephrology, 2010
- Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center ExperiencePLOS ONE, 2010
- The role of complement and Toll-like receptors in organ transplantationTransplant International, 2007
- Cardiomyopathy Is Linked to Complement ActivationThe American Journal of Pathology, 2002
- Role of complement in graft rejection after organ transplantationTransfusion Medicine Reviews, 2002